Citadel Advisors
TARA icon

Citadel Advisors’s Protara Therapeutics TARA Stock Holding History

Citadel Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,000
Closed -$72.9K – 14822
2026
Q1 		$72.9K Buy
+14,000
New +$82.9K ﹤0.01% 12227
2025
Q4 		– Sell
-15,400
Closed -$67K – 14043
2025
Q3 		$67K Buy
+15,400
New +$49.9K ﹤0.01% 12058
2025
Q2 		– Sell
-3,700
Closed -$15.8K – 15022
2025
Q1 		$15.8K Sell
3,700
-52,700
-93% -$235K ﹤0.01% 13303
2024
Q4 		$298K Buy
56,400
+54,600
+3,033% +$176K ﹤0.01% 9665
2024
Q3 		$3.29K Buy
1,800
+300
+20% +$616 ﹤0.01% 13670
2024
Q2 		$3.12K Sell
1,500
-700
-32% -$2.05K ﹤0.01% 13623
2024
Q1 		$8.82K Buy
2,200
+2,000
+1,000% +$6.45K ﹤0.01% 13530
2023
Q4 		$374 Sell
200
-800
-80% -$1.18K ﹤0.01% 14049
2023
Q3 		$1.67K Buy
1,000
+800
+400% +$1.83K ﹤0.01% 13824
2023
Q2 		$478 Sell
200
-500
-71% -$1.49K ﹤0.01% 14106
2023
Q1 		$2.17K Hold
700
– – ﹤0.01% 14194
2022
Q4 		$1.88K Buy
+700
New +$2.21K ﹤0.01% 14406

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Citadel Advisors's TARA Position: Q2 2026 in Review

Citadel Advisors increased its Protara Therapeutics (TARA) stake by 15% in Q2 2026, buying an estimated $779K and bringing the position to 1,232,365 shares worth $4.71M. The position accounts for ﹤0.01% of the portfolio, ranked #4827.

Citadel Advisors first reported a position in TARA in Q1 2017 and has held it in 26 quarters since. The position peaked at $5.57M in Q1 2026. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Citadel Advisors held 1,232,365 shares of Protara Therapeutics worth $4.71M as of Q2 2026.
  • Citadel Advisors bought 163,807 Protara Therapeutics shares in Q2 2026, an estimated $779K.
  • Protara Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4827 holding.
  • Citadel Advisors first reported a position in Protara Therapeutics in Q1 2017 and has held it in 26 quarters since.
  • Citadel Advisors's Protara Therapeutics position peaked at $5.57M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.